Carisma Therapeutics

(NASDAQ) CARM

Current PriceN/A

Market CapN/A

Since IPO (2023)-100%

5 Year-100%

1 Year-100%

1 Month-75%

Carisma Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$52.63M

Net Income (TTM)

$8.04M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 28, 2026

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 28, 2026

CARM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Carisma Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Steven Kelly, MBA

Website

www.carismatx.com

Headquarters

Philadelphia, PA 19104, US

CARM Financials

Key Financial Metrics (TTM)

Gross Margin

98%

Operating Margin

21%

Net Income Margin

15%

Return on Equity

-29%

Return on Capital

-42%

Return on Assets

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$40.04M

Operating Income

-$62.18M

EBITDA

-$56.83M

Operating Cash Flow

-$59.92M

Capital Expenditure

-$123.00K

Free Cash Flow

-$60.04M

Cash & ST Invst.

$18.83M

Total Debt

$2.48M

Carisma Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2025YOY CHG

Revenue

$45.25M

+1236.8%

Gross Profit

$45.25M

+1236.8%

Gross Margin

100.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$44.72M

+452.0%

EBITDA

$44.72M

+460.4%

Quarterly Fundamentals

Name

Q3 2025YOY CHG

Net Cash

$2.02M

-91.4%

Accounts Receivable

$1.64M

N/A

Inventory

$0.00

N/A

Long Term Debt

$609.00K

-28.9%

Short Term Debt

$153.00K

-93.8%

Return on Assets

1.23%

N/A

Return on Invested Capital

-42.04%

N/A

Free Cash Flow

$1.91M

+114.7%

Operating Cash Flow

$1.91M

+114.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

JSPRJasper Therapeutics, Inc.

JSPRJasper Therapeutics, Inc.$0.49+2.37%

ONCOOnconetix, Inc.

ONCOOnconetix, Inc.$1.03-0.96%

ENVBEnveric Biosciences, Inc.

ENVBEnveric Biosciences, Inc.$1.80-8.16%

SPRCSciSparc Ltd.

SPRCSciSparc Ltd.$11.44-0.87%

SLXNSilexion Therapeutics Ltd.

SLXNSilexion Therapeutics Ltd.$4.67-5.85%

SLRXSalarius Pharmaceuticals, Inc.

SLRXSalarius Pharmaceuticals, Inc.$0.84+29.23%

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$0.99-6.16%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$14.38-0.13%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.05-0.14%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.13-0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.19+0.14%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.14-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.50+0.02%

QQQInvesco QQQ Trust

QQQInvesco QQQ Trust$705.06-0.05%

Questions About CARM

What is the current price of Carisma Therapeutics?

Carisma Therapeutics is trading at N/A per share.

What is the 52-week range for Carisma Therapeutics?

Over the past 52 weeks, Carisma Therapeutics has traded between N/A and N/A.

How much debt does Carisma Therapeutics have?

As of the most recent reporting period, Carisma Therapeutics reported total debt of $762.00K.

How much cash does Carisma Therapeutics have on hand?

Carisma Therapeutics reported $2.78M in cash and cash equivalents in its most recent financial results.

What is Carisma Therapeutics’s dividend yield?

Carisma Therapeutics does not currently have a dividend yield.

Carisma Therapeutics

Carisma Therapeutics Financials at a Glance

CARM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Carisma Therapeutics

CARM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Carisma Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CARM

What is the current price of Carisma Therapeutics?

What is the 52-week range for Carisma Therapeutics?

How much debt does Carisma Therapeutics have?

How much cash does Carisma Therapeutics have on hand?

What is Carisma Therapeutics’s dividend yield?

Premium Investing Services